.

Laurie’s Abbreviation Index:

‘div’ – dividend 

‘m/m’ – month over month

‘y/y’ – year over year

‘Inven’ – inventories

‘mfg’ – manufacturing 

+/- – plus or minus, positive or negative

Color Key: Positive – Neutral – Negative

•Global Markets:  USA, Europe, Japan, China, Hong Kong Asia –  Neutral equity global set-up

•Commodities:  Gold, Silver, Oil and natgas, Softs, Industrial Metals

•Yields: Yields are flat

•Currencies:  US $ -.09%; $EUR +.10%

News: USA: PPI UE claims at 8:30 ET, 30y bond auction at 13:01 ET China: Exports > expected Japan: PPI y/y 7.2%
•Stocks DAL +3% Positive guide;  FAST, EPS, BABA, TCEHY Major holder has been selling Upgrades: DKNG, SPWR, SHOO, AXON, EOG FAANGMT: TSLA, NFLX, AAPL leaders, rest flat

•General: Leading:  China Internet, bitcoin, and Gold Miners Lagging: Bonds, US$, energy

Overview: USA indices consolidating ahead of PPI report. SPY 408.5 displays support of 407, and 405 with resistance at 410, 415, and 420. SPY expected move +/- 2.2. QQQ 313.7  with resistance 315,317, 320, and 325  and displays support of 312, and 310. QQQ expected move +/- 2.7.  Market positioned for outperformance by high short interest and midsized tech, and assets inversely correlated to US$ (gold, China). FAANGMT are not leading which may hold back the large cap indices. ARKK, IWM may outperform if short squeeze continues today. Note 0DTE have been buying dips and selling rips so expect intraday reversals.

Stocks to watch DAL, SHOP, NFLX, BABA, TSLA, COIN, AU, HL, STM MRK, TLT, FAST  Spec Names  RIOT

Pre-800ET
Earnings DAL, FAST, INFY, PGR

Indices KWEB, /BTC, GDX, JETS, ARKK, GLD, EEM, LIT, EWZ, ARKF, EFA, VXX, TLT, UUP, USO, XLE

S&P500 UAL, DAL, AAL, VFC, ALK, MRK, LUV, CTLT, FAST

IWM FRO, SPWR, RIOT, SHOO, NTLA, MSTR, VSTO

WSB RIOT, COIN, AFRM, UPST, BABA, MSTR

Movers BILI, FRO, UAL, SSYS, DAL, SPWR, LI, DAL, AU, STM, RIOT, GFI, JD, GDS, BX, PDD, FUTU, MT, SCLX, SRPT, CTLT, INFY, HOG, PLTK, FAST, FSLR, WAL

Trade Idea: MRK

In my analysis, Healthcare is strong and MRK is benefiting from an upgrade to $130 and positive drug trial results. Stock extended premarket and best entered on a pullback > 114